8.20

2.76% 0.22

After Hours: 8.20

Verastem Inc (VSTM)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Verastem Inc stock is traded at $8.20, with a volume of 2.30M. It is up +2.76% in the last 24 hours and up +41.14% over the past month. Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.

Previous Close:

$7.98

Open:

$7.91

24h Volume:

2.30M

Relative Volume:

0.93

Market Cap:

$742.62M

Revenue:

$30.91M

Net Income/Loss:

$-209.47M

P/E Ratio:

-2.464

EPS:

-3.3279

Net Cash Flow:

$-147.13M

1W Performance:

+13.57%

1M Performance:

+41.14%

6M Performance:

+41.14%

1Y Performance:

-22.35%

1-Day Range:

$7.72

$8.21

1-Week Range:

$7.00

$8.21

52-Week Range:

$3.43

$11.24

Verastem Inc Stock (VSTM) Company Profile

Name

Verastem Inc

Sector

Healthcare (1074)

Industry

Biotechnology (600)

Phone

(781) 292-4200

Address

117 KENDRICK STREET, NEEDHAM, MA

Employee

102

Twitter

@VerastemOncolog

Next Earnings Date

2026-08-06

Latest SEC Filings

VSTM's Discussions on Twitter

Compare VSTM vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VSTM Verastem Inc	8.20	617.64M	30.91M	-209.47M	-147.13M	-3.3279
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Verastem Inc Stock (VSTM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-12-26	Resumed	BTIG Research	Buy
Feb-04-26	Initiated	H.C. Wainwright	Buy
Oct-16-25	Resumed	Cantor Fitzgerald	Overweight
Apr-10-25	Initiated	Jefferies	Buy
Mar-24-25	Reiterated	H.C. Wainwright	Buy
Dec-31-24	Reiterated	BTIG Research	Buy
Sep-30-24	Initiated	Guggenheim	Buy
Nov-21-23	Resumed	BTIG Research	Buy
Sep-27-23	Initiated	B. Riley Securities	Buy
Jun-15-23	Upgrade	Mizuho	Neutral → Buy
Sep-07-22	Resumed	Alliance Global Partners	Buy
Apr-29-22	Resumed	Cantor Fitzgerald	Overweight
Apr-14-22	Initiated	RBC Capital Mkts	Outperform
Mar-09-22	Initiated	Truist	Buy
Jul-01-21	Initiated	Alliance Global Partners	Buy
May-24-21	Upgrade	BTIG Research	Neutral → Buy
Jun-20-19	Downgrade	BTIG Research	Buy → Neutral
May-10-19	Downgrade	Raymond James	Outperform → Mkt Perform
Jul-13-18	Initiated	BTIG Research	Buy
May-02-18	Initiated	Seaport Global Securities	Buy
Mar-08-18	Initiated	B. Riley FBR, Inc.	Buy
Sep-07-17	Reiterated	H.C. Wainwright	Buy
Apr-13-17	Initiated	Oppenheimer	Outperform
Mar-24-17	Reiterated	H.C. Wainwright	Buy
Sep-29-15	Downgrade	Cantor Fitzgerald	Buy → Hold
Sep-29-15	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Sep-29-15	Downgrade	Jefferies	Buy → Hold
Sep-29-15	Downgrade	Raymond James	Strong Buy → Outperform
Sep-28-15	Downgrade	Mizuho	Buy → Neutral
Sep-28-15	Downgrade	ROTH Capital	Buy → Neutral
Sep-09-15	Initiated	Raymond James	Strong Buy
May-12-15	Reiterated	UBS	Buy
Apr-08-15	Initiated	H.C. Wainwright	Buy
Jan-23-15	Reiterated	ROTH Capital	Buy
Jul-08-14	Resumed	Oppenheimer	Perform
Feb-11-14	Initiated	Mizuho	Buy

View All

Verastem Inc Stock (VSTM) Latest News

Sep 06, 2026

(VSTM) Movement as an Input in Quant Signal Sets - Stock Traders Daily

Sep 06, 2026

Sep 02, 2026

Verastem Oncology to Participate in Upcoming September Investor Conferences - Business Wire

Sep 02, 2026

Aug 31, 2026